initiated by conformational changes elicited or trapped by binding of ESCs and that these movements are restricted by mutations associated with resistance against ESCs. ________________________________________ In recent years, the sexually transmitted infection gonorrhea has become increasingly difficult to treat due to antibiotic resistance exhibited by its etiological agent Neisseria gonorrhoeae. Penicillin G was effective for treating gonorrhea for over 40 years, but was discontinued in 1986 as the recommended treatment due to increasing prevalence of resistant strains. Tetracyclines and fluoroquinolones were similarly withdrawn (in 1986 and 2007, respectively), leaving only the extended-spectrum cephalosporins (ESCs), ceftriaxone and cefixime, and the macrolide azithromycin as recommended treatments (1) . In 2010, oral cefixime was removed as a recommended treatment, and supplanted with ceftriaxone and azithromycin as a dual therapy (2). Unfortunately, there have been several recent reports of N. gonorrhoeae strains exhibiting resistance to both ceftriaxone and azithromycin, raising fears that untreatable gonorrhea will emerge in the near future (3, 4) .
A sentinel strain in the emergence of cephalosporin-resistant (Ceph 2 The minimum inhibitory concentrations (MICs) of ceftriaxone and cefixime for H041 are 2 and 8 μg/ml, respectively, well above the breakpoints (>0.25 µg/ml) for these antibiotics (6) . H041 is also resistant to many other antibiotics, including azithromycin, fluoroquinolones and tetracycline, and is therefore considered the first pan-resistant strain of N. gonorrhoeae. A second Ceph R strain termed F89 emerged later in France and again in Spain (7, 8) . Similar to H041, this strain also exhibits resistance to several classes of antibiotic in addition to ESCs.
N. gonorrhoeae utilizes a number of mechanisms to elevate resistance to β-lactams, including having mutated alleles of penA, mtrR, penB, and ponA, along with an unknown determinant (9) (10) (11) (12) . All these mechanisms contribute to resistance, but the key difference in Ceph R strains is acquisition of a mosaic penA allele containing over 60 amino acid mutations compared to penA alleles from either penicillin-resistant (e.g. FA6140) or antibiotic-susceptible strains (e.g. FA19) (6) . penA encodes penicillin-binding protein 2 (PBP2), an essential peptidoglycan transpeptidase that catalyzes the formation of peptide cross-links between glycan strands via an acyl-enzyme transpeptidation mechanism during the latter stages of peptidoglycan synthesis (13) . ESCs, and indeed all β-lactam antibiotics, mimic the cell-wall peptide and form a long-lived acyl-enzyme complex with the PBP, thus preventing transpeptidation and leading to loss of cell viability. The transpeptidase (TPase) domain in PBP2 contains the archetypal active-site motifs for PBPs: SxxK, SxN, and KTG motifs, where x signifies variable residues (for PBP reviews see (14, 15) ). A key residue in PBP2 is Ser310 on the SxxK motif because this is the activesite nucleophile that reacts with both peptide substrates and β-lactam antibiotics to form an acylenzyme complex.
Previously, we reported that allelic replacement of the penA allele in FA19 with the mosaic penA allele from H041 (penA41) can transform the penicillin-and cephalosporin-susceptible strain FA19 to full resistance for cefixime and ceftriaxone in the absence of any other resistance determinants (16) . In addition, we showed that among the 60 or so mutations present in the mosaic PBP2 variants, a subset comprising I312M, V316T, G545S and N512Y are responsible for much of the elevated cephalosporin resistance in N. gonorrhoeae strain 35/02, an intermediate cephalosporin resistant (Ceph I ) strain (17) . Compared to penA35, penA41 encodes 13 new or different amino acid mutations. Of these, three mutations (A311V, V316P and T483S) contribute to the increased resistance to ESCs conferred by penA41 above that conferred by penA35 (16) . Together, these mutations increase the MICs of cefixime and ceftriaxone for H041 by lowering the rates of acylation of PBP2 by up to 12,000-fold (16) and firmly establish PBP2 as the prime determinant of cephalosporin resistance in N. gonorrhoeae.
Against the background of increasing resistance to ESCs and verified treatment failures of ceftriaxone and cefixime against N. gonorrhoeae strains, it is crucial to understand how PBP2 interacts with these antibiotics and how mutations in PBP2 lower acylation rates while retaining sufficient transpeptidase activity to support viability. Using a construct comprising the TPase domain of PBP2, we present crystal structures of the TPase construct of PBP2 acylated with ceftriaxone or cefixime, as well as structures in apo form and bound by phosphate in the active site. These structures reveal conformational changes within the active site and the surrounding region elicited by acylation. We propose that twisting and rolling of the β3 strand in the active site, with concomitant adjustment of the KTG motif is a critical component of acylation, and that mutations associated with cephalosporin resistance hinder these conformational changes.
RESULTS

Structure of the TPase domain of two forms of PBP2
We reported previously that PBP2 lacking its N-terminal domain and 15 residues from a protruding loop (hereafter referred to as tPBP2) exhibits essentially identical k 2 /K S acylation rates for penicillin G and other antibiotics as the fulllength protein (18) . To establish whether any structural changes occur when the TPase domain of PBP2 is expressed independently of the N-terminal domain and for the purposes of comparison with acylated structures, we determined the crystal structure of tPBP2. Crystals were obtained in two crystal forms in the P2 1 space group, termed tPBP2 APO and tPBP2
PO4
, depending on whether phosphate ions were observed in the structure (the former form was obtained from tPBP2 prepared in Tris buffer, the latter from protein prepared in phosphate-containing buffer; see Methods). Both forms crystallized with two molecules in the asymmetric unit, but with slightly different cell dimensions. The two molecules in the asymmetric unit of the tPBP2 APO structure superimpose on each other with a root-mean square deviation (RMSD) of 1.0 Å between common C α atoms (Fig. S1A) , while the two molecules of the tPBP2 PO4 structure superimpose on each other with RMSD of 0.94 Å (Fig. S1B) . The data collection and model refinement statistics are shown in Table 1 .
As expected, the structure of tPBP2 APO superimposes closely with the TPase domain of full-length PBP2 (19) , including the active-site residues (Figs. S2A and B). The RMSD is 0.69 and 1.07 Å for molecules A and B of tPBP2 APO , respectively, for common C α atoms with the corresponding molecules of full-length PBP2, and differences between the two structures are minimal. The only major difference is that there is electron density corresponding to the β3-β4 loop for molecule B of tPBP2 APO , whereas density for this region is lacking in both molecules of full-length PBP2.
The tPBP2 PO4 structure is so termed because it contains a phosphate ion bound in the active site of the enzyme. The phosphate lies between α2 (containing the SxxK motif) and β3 (containing the SxN motif), and replaces a water molecule observed at this position in the tPBP2 APO structure (Fig. 1A ) (for nomenclature of secondary structure in PBP2 see (19) ). The phosphate is within hydrogen-bonding distance of the side chains of Ser310, Ser362, Thr498 and Thr500, with an additional hydrogen bond to the main chain amide of Gly546 via a bridging water oxygen (Fig. 1B) . A sulfate occupying a similar position as the phosphate has been observed in the crystal structure of S. pneumoniae PBP2x (20) and also a sulfonic acid group (as part of a MES molecule) in the structure of PBP1a, also from S. pneumoniae (21) .
A phosphate bound in the active site elicits a conformational change in β3
The tPBP2 APO and tPBP2 PO4 structures superimpose upon each other with an RMSD of 0.95 Å between A molecules (Fig. S3A ) and 0.66 Å between B molecules (Fig. S3B) , indicative of overall similar structures, but with changes evident in the β-hairpin region (β2a-β2d) and the α1-β1 and β5-α11 loops. In contrast to tPBP2 APO , the β3-β4 loop is disordered in both molecules of the asymmetric unit of tPBP2
PO4 . The comparison also shows that in the active site of tPBP2 PO4 , the side chain of Thr498 (the second residue of the KTG motif) has rotated away from the main chain amide of Gly546 to form a new hydrogen bond with the phosphate (Fig. 1C) . In tandem, the KTG motif of β3 has twisted toward the active site and there is a similar movement of β4 alongside, albeit of lesser magnitude. The different rotamers for Thr498 in the two structures are clearly supported by unbiased difference electron density (Fig. S4) . Far from being an anomaly, the conformational change elicited by the phosphate has implications for the mechanism of acylation, as will be discussed later.
Acyl-enzyme structures of tPBP2 with extendedspectrum cephalosporins tPBP2 acylated by cefixime: The extendedspectrum cephalosporin cefixime is composed of a β-lactam ring fused with a six-membered dihydrothiazine ring, an allyl group at the C3 position, a carboxylate at the C4 position, and an R1 group at the C7 position comprising an aminothiazole ring and carboxymethyl oxime side chain ( Fig. 2A) . The crystal structure of tPBP2 acylated by cefixime (tPBP2 CFX ) was determined at 1.7 Å resolution by soaking crystals of tPBP2 APO with the antibiotic (Table 1 ). An unbiased |Fo|-|Fc| difference electron density map clearly identifies the covalent bond between C8 of cefixime and Ser310 in both molecules of the asymmetric unit (Figs. 2B and C). Electron density is observed for the majority of the cefixime molecule in both molecules except for the carboxymethyl oxime side chain, which appears to be disordered. Overall, the conformation of cefixime is the same in both molecules of the asymmetric unit (Fig. 2D) .
Contacts made by cefixime with tPBP2 comprise a number of hydrogen-bonding interactions (Figs. 2B and C) . One of these is between the carbonyl oxygen of the cefixime ester and the main chain amides of Ser310 and Thr500, which together comprise the oxyanion hole formed during the reaction with both peptidoglycan substrate and β-lactams (22, 23) . In addition, the cephalosporin carboxylate forms hydrogen bonds with the hydroxyl groups of Thr498 and Thr500 of the KTG motif, and Ser362 of the SxN motif. There are also hydrogen bonds involving a water molecule that bridges between the carboxylate and Gly546 at the beginning of α11. Other hydrogen bonds occur between the carbonyl oxygen preceding the aminothiazole ring (R1 group) of cefixime and the side chain amide nitrogen of Asn364 from the SxN motif, and between the amino group of the aminothiazole and the side chain of Glu307 and the main chain carbonyl oxygen of Arg502.
tPBP2 acylated by ceftriaxone: Ceftriaxone has a similar structure as cefixime except for a dioxotriazine ring (R2) at the C3 position in place of the allyl in cefixime, and a methyloxime group in place of carboxymethyl oxime in the R1 group (Fig. 3A) . The crystal structure of tPBP2 acylated with ceftriaxone (tPBP2 CRO ) was solved at 1.8 Å resolution by soaking crystals of tPBP2 APO (Table  1) . Like the cefixime-acylated structure, unbiased electron density shows ceftriaxone covalently bound to Ser310 in both molecules of the asymmetric unit (Figs. 3B and C) . The electron density for ceftriaxone is generally similar in both molecules of the asymmetric unit, except for being slightly weaker overall in molecule B.
When comparing molecules of the asymmetric unit, a striking difference in the electron density for ceftriaxone is the presence of the C3 dioxo-triazine ring in molecule A (R2 group). For ceftriaxone, this group is normally eliminated during acylation (24, 25) , but the electron density in molecule A indicates that the leaving group has remained attached even though acylation has completed (as indicated by the covalent bond between Ser310 and ceftriaxone). This suggests that an intermediate stage has been trapped in molecule A of the asymmetric unit, whereas the reaction has proceeded to completion in molecule B. The C3 dioxy-triazine ring packs between Tyr544 and Tyr543 ( Fig. 3B) , with an imperfect stacking arrangement with Tyr544. The retention of the leaving group in molecule A may result from a symmetry contact, where Arg258 from a symmetry-related molecule in the crystal lattice interacts with one of the oxygens of pyridine ring (Fig. S5 ), and such trapping may have impeded its elimination during acylation. This symmetry interaction is not observed in the B molecule. To the best of our knowledge, this is the first time the leaving group of a cephalosporin has been observed in an acylated-PBP structure.
A consequence of the C3 leaving group of ceftriaxone remaining in molecule A of the structure is a difference in the configuration of the dihydrothiazine ring. In molecule A, the dihydrothiazine ring remains in an endocyclic methylene form, but in molecule B, where the C3 leaving group has been eliminated, the ring has rearranged to the exocyclic form (Fig. 3D) . Consistent with this, elimination of the C3 substituents of ceftazidime and cefoperazone also elicits a rearrangement to the exocyclic form in crystal structures of P. aeruginosa PBP3 (26, 27) .
Interactions made by ceftriaxone in the active site of tPBP2 are essentially the same as for cefixime, including those made by the aminothiazole ring (R1 group) with Glu307 and Arg502, and the ceftriaxone carboxylate with Thr483, Thr500, and Gly546 via a bridging water molecule. Similar to the carboxymethyl oxime in cefixime, the methyloxime group of ceftriaxone does not appear to interact with the enzyme. In fact, the only significant difference in binding mode between the two cephalosporins is the presence of the R2 moiety (C3 dioxo-triazine group) in molecule A of the ceftriaxone structure.
Acylation by cefixime elicits conformational changes in tPBP2
Equivalent Cα atoms of the tPBP2 CFX structure superimpose onto the tPBP APO structure with an RMSD of 0.8 and 1.8 Å for molecules A and B, respectively. The higher RMSD for the B molecule superimposition reflects the large structural changes in the β3-β4 loop, which is mostly ordered in molecule B (Fig. S6 ), but absent in molecule A of both structures. Across most of the PBP2 molecule, conformational changes elicited by acylation with cefixime are relatively few and most occur in the active-site region (Fig. 4A) . The most notable change is rearrangement of the β3-β4 loop in the acylated structure, comprising both twisting of the loop and rolling toward the active site (Fig.  4B) . A major consequence of this shift is a striking movement of Tyr509 from the apex of this loop distant from the active site in the apo structure to form part of a cluster of side chains near the R1 group of cefixime (Fig. 4C) . This amounts to a 12 Å shift of its Cα atom and 22 Å for its hydroxyl group. In its new position, the side chain hydroxyl of Tyr509 is within hydrogen bonding distance of Glu307, which resides on the loop preceding the SxxK motif. Tyr422 is also part of this cluster and has shifted from forming a hydrogen bond with Thr500 in the tPBP2 APO structure to contacting Arg502. By shifting, it avoids a steric clash with the R1 group of cefixime and in its new position, stacks against the aminothiazole ring of cefixime. Asp511 also moves over 10 Å to contact Arg502. Overall, the grouping of Tyr422, Tyr509, Asp511, Glu307 and Arg502 appears to occlude the active site when cefixime is bound.
In addition to the β3-β4 loop, β3 itself also twists toward cefixime and in so doing, repositions the KTG motif (Fig. 4D ). This brings the amide nitrogen of Thr500 to within hydrogen bonding distance (3.1 Å) of the cefixime carbonyl, an interaction that is necessary for correct formation of the oxyanion hole that stabilizes the negative charge of the oxygen during acylation. Thr498 has also moved toward cefixime by rotating approximately 35 o about the β3 axis and in tandem, its side chain has also rotated. The new rotamer position results in loss of a hydrogen bond with Gly546 and gain of hydrogen bonds with the cefixime carboxylate and with Thr483 on the α10-β3 loop. A further consequence of the reorientation of Thr498 is displacement of a water molecule, which now hydrogen bonds with the hydroxyl groups of Thr498 and Thr483, as well as the side chain amino group of Lys497 and the main chain carbonyl of Met359 (Fig. S7) .
Another structural difference in the tPBP2 CFX structure compared to its apo equivalent is movement of Tyr543 and Tyr544, both of which reside on the β5-α11 loop. In the acylated structure, both tyrosines move slightly closer to the active site (Fig. 4B) . The movement of the Tyr544 side chain is more pronounced when comparing the B molecules of the asymmetric unit rather than molecule A (Fig. S8) . Additionally, the electron density for this part of the α10-β3 loop is weaker in the apo structure rather than when acylated by cefixime.
Ceftriaxone elicits conformational changes in tPBP2 APO similar to those by cefixime The RMSD values for superimpositions of the tPBP2 CRO structure with tPBP2 APO are 0.7 and 1.7 Å for molecules A and B, respectively. Similar to tPBP2 CFX , molecule B has a higher RMSD value due to changes in the β3-β4 loop. This superimposition paints a very similar view as the tPBP2 APO vs. tPBP2 CFX comparison, because essentially the same conformational changes are observed with ceftriaxone ( Fig. 5) . Thus, the same striking movement in β3-β4 toward the active site occurs to form the cluster of residues around the aminothiazole ring of ceftriaxone, β3 twists to reposition the KTG motif to form the oxyanion hole, and the rotamer of Thr498 is altered. Tyrosines 543 and 544 also move in a similar way as in the cefixime-acylated structure. Again, the movement of Tyr544 is more pronounced in molecule B of the asymmetric unit and occupies a position slightly closer to the antibiotic compared to cefixime (Fig. S8) . Finally, the two acylated structures superimpose very closely with each other (RMSD values are 0.3 and 0.5 Å for molecules A and B, respectively), indicating that they both converge to essentially the same conformational state after acylation (Fig. 6) .
Binding of phosphate alone elicits the acylated conformational state
When comparing the structure of tPBP2 PO4 with the two acylated structures, it is clear that all three overlap very closely with RMSD values of approximately 1.0 Å between structures (Fig. 7) . The convergence of these structures shows that the phosphate alone can elicit the same conformational changes associated with the acylated state, including twisting of β3 to form the oxyanion hole, rotation of the Thr498 side chain, and movement of the β5-α11 loop. Excluded from these changes is rearrangement of the β3-β4 loop because this is disordered in both molecules of the tPBP2 PO4 structure. The spatial overlap of the phosphate with the β-lactam carboxylates of both cefixime and ceftriaxone (Fig. 7, inset ) strongly suggests that recognition of the cephalosporin carboxylate is primarily responsible for the conformational changes in the active site that precede acylation. The carboxylate group is a common feature of all β-lactams and its negative charge is likely responsible for the shift.
T498A mutant of tPBP2 does not react with Bocillin-FL
The change in side-chain rotamer and hydrogen bonding interactions as a result of acylation led us to test whether T498 is necessary for acylation using the fluorescent penicillin, Bocillin-FL (28) . SDS-PAGE gels show that a T498A mutant of tPBP2 is labeled only weakly by Bocillin-FL compared to the wild-type construct (Fig. S9) . Moreover, the T498A mutant was crystallized and its structure does not exhibit any changes aside from the absence of the threonine side-chain. Hence, it appears that Thr498 is required for efficient acylation, as would be expected from its key involvement in the conformational changes in the active site.
DISCUSSION
The emergence of N. gonorrhoeae exhibiting resistance to ESCs is a major threat to public health and addressing the problem requires an understanding of the molecular mechanisms underpinning resistance. To reveal how mutations confer resistance, however, it is first necessary to understand how PBP2 recognizes and reacts with ESCs. We have taken a major step toward this goal by solving crystal structures of PBP2 with the two cephalosporins used to treat gonorrhea and using these structures to understand the molecular mechanism of acylation. Our data suggest that ligand-induced conformational changes are required for PBP2 to undergo efficient acylation and also suggest how specific mutations confer resistance.
Mapping conformational changes that result from acylation provides the first indication of molecular mechanism. We find that a number of important conformational changes occur in the active site of PBP2 as a result of acylation by ceftriaxone or cefixime. The most important of these appears to be twisting of β3 toward the active site. This orients the KTG motif such that the amide nitrogen of Thr500 is positioned properly to form the oxyanion hole along with the amide of Ser310. The geometry of the oxyanion hole, including the distance to the tetrahedral oxyanion, is critical for rate enhancement and, although the transition state cannot be seen in the post-covalent state, the amides are within hydrogen bonding distance of the ester linkage carbonyl of ceftriaxone and cefixime in the crystal structures. In the absence of β3 twisting, the geometry of the transition state would be suboptimal, with a negative impact on the rate of acylation. The β3 strand also undergoes transitions after acylation by antibiotics in other PBP structures, including S. aureus PBP2a (29, 30) , E. faecalis PBP4 (31) , and the Actinomadura R39 DDpeptidase (32) . In some of these, β3 appears to twist outwards from the active site when acylated by β-lactams rather than inward (30, 31) . By creating an energetic barrier against acylation, the twisting of β3 in S. aureus PBP2a has been suggested to be a mechanism for lowering reactivity with β-lactams that contributes to resistance (29) . However, the observation of similar transitions occurring in nonmutated PBPs from susceptible organisms suggests it is more likely a facet of the PBP reaction.
The twisting of β3 to bring the KTG motif toward the active site of PBP2 begs the question as to how binding of cephalosporin elicits this conformational change because, without knowing its trigger, it will be difficult to understand the effect of resistance mutations. The fortuitous binding of a phosphate ion in the active site of tPBP2 PO4 suggests that recognition of the β-lactam carboxylate is the key event. There are two lines of evidence to support this assertion. Firstly, the conformational changes observed in the active site of the phosphate-bound structure (tPBP2 PO4 ) are essentially the same as those seen in both the cefixime-and ceftriaxone-acylated structures when compared to tPBP2 APO , showing that the tPBP2 PO4 structure is representative of an acylated conformation. Secondly, the phosphate binds at a position that overlaps closely with the carboxylate of the β-lactams (Fig. 7) . Taken together, these data are consistent with recognition of the carboxylate being the primary signal for conformational change in the KTG motif when PBPs bind and react with β-lactam antibiotics. This can be thought of as an induced-fit mechanism, but it is also possible that binding of phosphate selects the acylationcompetent state from a population of two or more states.
Based on the structural data for PBP2 PO4 and the two acylated structures, we propose that recognition of the β-lactam carboxylate by Thr498 is the key event responsible for the twisting of β3. In PBP2 APO , the side chain of Thr498 projects away from the active site and forms a hydrogen bond with the amide nitrogen of Gly546 (Fig. 1A) . When a cephalosporin binds PBP2, the side chain of Thr498 rotates, so that the hydrogen bond with Gly546 is broken and a new bond is formed with the cephalosporin carboxylate (Figs. 2 and 3) . While the temporal sequence of events cannot be ascertained unambiguously in the post-covalent state, it is reasonable to speculate that the new hydrogen bond between Thr498 and the β-lactam carboxylate triggers rotation of β3 and subsequent movement of the KTG toward the active site (or if the mechanism is conformational selection, traps β3 when twisted toward the active site). Consistent with its central role in the conformational change, a side chain hydroxyl (i.e. threonine or serine) is invariant at this position in all active-site serinebased PBPs. Moreover, tPBP2 containing a T498A mutation reacts much slower with Bocillin-FL than its wild-type counterpart and a crystal structure of the mutant shows no structural perturbations other than the loss of the side chain (Fig. S9) .
In addition to the KTG motif, there are other conformational changes associated with acylation in PBP2. The most significant of these is rolling of the β3-β4 loop from a solvent-exposed extended conformation in PBP2 APO to a position where the loop appears to occlude the active site. This transition occurs in both acylated structures. This is the first time the β3-β4 loop has been observed in a PBP occupying two distinct conformations where both states are ordered in the crystal structure. In its new closed position in the acylated structures, the loop forms a network of interactions around the R1 group of the cephalosporin involving Asp511, Tyr509, Arg502, Glu307, and Tyr422 (Fig. 4) . These interactions may contribute to the specificity for cephalosporins (33), but it is also possible that occlusion of the active site promotes the acylation mechanism.
In tPBP2, the transition in the β3-β4 loop seems to be elicited by acylation because it occurs in both ceftriaxone-and cefixime-acylated structures. However, in the structure of A. baumannii PBP3, the β3-β4 loop adopts a conformation similar to acylated tPBP2 even though the enzyme is in apo form (34) . This suggests that the β3-β4 loop can occupy both open and closed states when the PBP is in the apo form and that the closed form predominates after acylation. This is in concordance with the inherent flexibility of the β3-β4 loop that is a common feature of PBPs, including PBP2. For instance, in the crystal structure of PBP2 derived from the penicillin-resistant strain FA6140, the β3-β4 loop is ordered in one molecule of the asymmetric unit, but disordered in the other (18) . Similar variations in degree of order and conformation of this loop are also observed in other PBPs, such as PBP1a, PBP2b and PBP2x of S. pneumoniae, PBP3 of P. aeruginosa, and PBP1a of A. baumannii (21, (34) (35) (36) (37) . Given the involvement of crystal packing interactions in this region, interpretation of changes in the β3-β4 loop can be uncertain, especially when interpreting the impact of mutations implicated in antibiotic resistance. Nevertheless, plasticity of the β3-β4 loop is consistent with the apparent role it plays in acylation of PBP2 by cephalosporins, as seen in the tPBP2 CFX and tPBP2 CRO structures.
Another interesting facet of the tPBP2 structures is the mobility of the β5-α11 loop, which is generally closer to the active site in both acylated structures compared to the apo structure. In molecule A of the tPBP2 CRO structure, Tyr544 stacks against the dioxytriazine leaving group of ceftriaxone, which has remained attached to the antibiotic. These two tyrosines are highly conserved in PBPs from Gram-negative bacteria that are involved in cell division (FtsI homologs), alongside two conserved glycines (Fig. S10) . Similar flexibility of this region has also been observed in other PBP structures (26, 27, 34, 38) . In P. aeruginosa PBP3 (a homolog of N. gonorrhoeae PBP2), the equivalent residues (Tyr532 and Phe533) along with Phe503, have been characterized as an aromatic "wall" that accommodates the gem-dimethyl group of ceftazidime (26) . Such a group is lacking in both ceftriaxone and cefixime, however. It is interesting to note that Tyr544 also moves in the PBP2 CFX structure, even though cefixime lacks a C3 leaving group. Hence, mobility of this region may be associated with transpeptidase activity rather than being an important factor in the reaction with cephalosporins.
Whether the conformational changes elicited by ESCs also occur during the natural peptidoglycan crosslinking reaction is an interesting question to consider. Of the three major shifts observed, the most likely to occur during transpeptidation is twisting of β3 because the β-lactam carboxylate that elicits this change mimics the C-terminal carboxylate of the peptide substrate. For the reason given above, the shift of the β5-α11 loop may also occur during peptidoglycan crosslinking, and given its proximity with the R2 side of the cephalosporin, it seems more likely this would involve the acceptor peptide, rather than the donor. Finally, the situation with the β3-β4 loop is less clear. The interactions this loop makes with the R1 region of ESCs appear highly specific and yet it is very likely that inherent flexibility of the loop is important for transpeptidase activity. Clarity on these questions must await structural information showing PBPs in complex with peptide substrates.
The structures of PBP2 in complex with ceftriaxone and cefixime afford the first interpretation of mutations associated with Ceph R in the context of acylated structures. There are 61 mutations in PBP2 from the Ceph R strain H041 and it has been established previously that at least six of these are important for conferring resistance. Three mutations were identified in the penA35 allele from the Ceph I strain 35/02 (17) and an additional three were identified in penA from H041 (16) . Mapping these mutations onto the structure of PBP2 acylated by ceftriaxone shows that they are distributed around the binding site, though none make direct contact with the antibiotic (Fig. 8) . Three mutations (V316P, I312M and A311V) are found on α2, which contains Ser310 at its N-terminal end, but none are particularly near ceftriaxone. The side chain of Val311 is closest, but lies on the opposite side of the helix to Ser310.
The T483S mutation resides on the α10-β3 loop but again, does not contact ceftriaxone directly. However, it occupies a position where it can hydrogen bond with Thr498 via its side chain hydroxyl and, given the important role that Thr498 appears to play in the mechanism of acylation, could impact reactivity with cephalosporins. In the acylated state, Thr498 also hydrogen bonds with Ser362 of the SxN motif and Lys497 of the KTG motif. However, it is worth noting that Thr483 is a serine in PBP2 from H041 and thus should also be capable of forming the same hydrogen bond with Thr498. This makes the role of this residue in cephalosporin resistance unclear at the present time.
Another mutation known to contribute to cephalosporin resistance is N512Y, which is present on the β3-β4 loop (17) . As noted above, this region undergoes a major transition between apo and acylated states and it is possible that mutation of Asn512 to tyrosine hinders the conformational change. Some PBPs contain mutations in the β3-β4 loop that are associated with resistance (39, 40) and if similar transitions occur when these proteins are acylated by β-lactams, they may act in a similar way.
Finally, the Ceph R mutation that appears to have the most obvious consequence is G545S. In wild-type PBP2, Gly545 lies on the β5-α11 loop close to Thr498 of the KTG motif. Given the central role that Thr498 likely plays in the mechanism of acylation, it is probable that the hydroxyl group introduced by the G545S mutation will form a hydrogen bond with the hydroxyl of Thr498, thus hindering rotation of the latter's side chain after binding of the cephalosporin. In turn, this may make rotation of β3 more difficult and impede formation of the oxyanion hole required for acylation. Such loss of flexibility in β3 would hinder the acylation process by increasing the energetic cost required for formation of the transition state.
The probable mechanism of the G545S mutation is reminiscent of mutations at position 501 in PBP2 that are associated with cephalosporin resistance (41) (42) (43) . This position constitutes the transition point between β3 and the β3-β4 loop. The crystal structure of an A501T mutant has been solved and, similar to G545S, the side chain hydroxyl of Thr501 forms a new hydrogen bond (with Glu307 prior to the SxxK motif) that would be expected to reduce flexibility in this region (44) . Such similarity in mechanisms at different positions in the protein may be the beginning of a consistent pattern emerging to explain cephalosporin resistance mediated by mosaic variants of PBP2.
The key role of the β-lactam carboxylate in the acylation mechanism of PBP2 has implications for drug design of new antimicrobials that target PBP2 and potentially other PBPs. As noted, the cephalosporin carboxylate appears responsible for the twisting of β3 to form the oxyanion hole in PBP2 and the presence of a carboxylate or sulfate is a common feature of β-lactams and also of some new antimicrobials under development, including diazabicyclooctanes (45, 46) . Similarly, other compounds under development include boronate groups at the equivalent position (47) . The apparent impairment of β3 twisting in PBP2 by the G545S mutation suggests that the efficacy of an antimicrobial drug candidate containing a carboxylate or similar group may be compromised by the same resistance mechanism. This would also apply to other PBPs if twisting of β3 is also a requirement for efficient acylation. This being the case, then new antimicrobials directed against resistant strains should avoid inclusion of a carboxylate or equivalent. It is interesting to note that neutral β-lactams lacking the carboxylate inhibit PBP3 from B. subtilis and PBP2a from S. aureus at a similar level of activity to the same β-lactams containing a carboxylate (48) . By not relying on β3 rotation for activity, such compounds may offer a means to circumvent this type of resistance mechanism.
In conclusion, crystal structures of N. gonorrhoeae PBP2 in complex with cefixime and ceftriaxone, which are or have been used to treat gonorrhea infections, indicate a mechanism of acylation that involves twisting of the KTG motif of β3 to form the oxyanion hole and rolling of β3-β4. The trigger for the conformational change in β3 (or conformational trapping) appears to be recognition of the β-lactam carboxylate by Thr498, whose side chain disengages from a hydrogen bond with Gly545 to form a new bond with the carboxylate. Finally, these structures begin to show the impact of mutations of mosaic PBP2 variants from Ceph I or Ceph R strains of N. gonorrhoeae and in particular, highlight the importance of the G545S mutation in hindering movement of Thr498 toward the active site. This now sets the stage for a more exhaustive examination of resistance mechanisms via structural studies of PBP2 from cephalosporinresistant strains.
EXPERIMENTAL PROCEDURES
Cloning and expression of the transpeptidase domain of wild-type PBP2: Previously, we have reported the cloning of a truncated construct of PBP2 (here termed tPBP2) comprising only the transpeptidase (TPase) domain of wild-type PBP2 (18) derived from FA19, a penicillin-and cephalosporin-susceptible strain of N. gonorrhoeae (49) . This construct has essentially identical k 2 /K S acylation constants as full-length PBP2 for a range of antibiotics. tPBP2 is expressed as a fusion with maltose-binding protein (MBP), separated by a tobacco etch virus (TEV) protease site and with a hexa-histidine tag at its N-terminus. Nucleotides encoding amino acids 283-297 were excluded from the construct, because in the crystal structure of full-length PBP2, these form a loop that projects from the TPase domain (19) and was predicted to hinder crystallization. Residues Pro282 and Arg298 are connected with a non-native glycine linker.
After transformation of the wild-type construct into E. coli BL21 (DE3) cells, 2 liters of cell culture were grown at 37 o C. Protein expression was induced by addition of 0.3 mM isopropyl-β-Dthiogalactoside, followed by overnight incubation at 20 o C. After centrifugation, cells were lysed in 20 mM Tris•HCl, pH 8.0, 500 mM NaCl, and 10% glycerol (TNG buffer) and the supernatant was passed over a 5 ml HisTrap TM FF Ni 2+ -affinity column (GE Healthcare, Piscataway, NJ). After elution with 0-500 mM imidazole gradient in TNG, the fusion protein was concentrated and digested with His 6 -tagged TEV protease at a molar ratio of 50:1, followed by overnight dialysis at 4 o C against TNG. The digested protein was then passed over a 5 ml HisTrap TM HP Ni 2+ -affinity column, washed with TNG, and tPBP2 was eluted by a TNG/15 mM imidazole step gradient. The protein was then dialyzed overnight against 50 mM phosphate, pH 7.1, with 10% glycerol and loaded onto 5 ml HiTrap TM SP FF ion exchange column (GE Healthcare, Piscataway, NJ) equilibrated in the same buffer. The protein was eluted by a 0-500 mM NaCl linear gradient in the same buffer and tPBP2-containing fractions were pooled. The protein was concentrated to 37 mg/ml using a 10-kDa cut-off Amicon concentrator (MilliporeSigma, Burlington, MA) at 4°C. The concentrated protein was flash frozen in liquid nitrogen and stored at ˗80°C.
Crystallization: Prior to crystallization trials, tPBP2 was diluted to 13 mg/ml in two buffers: TNG or PNG (50 mM phosphate, pH 7.1, 10% glycerol, 180 mM NaCl). Crystallization trials were performed in 96-well sitting drop format using a Gryphon liquid dispensing system (Art Robbins, Sunnyvale, CA) in which 200 nl protein was mixed with 200 nl well solution. The protein was screened against a number of sparse matrix screens, including JCSG Cores I-III and Suite+ (Qiagen, Germantown, MD) with incubation at 21 o C. A number of crystallization hits were obtained and all were in solutions containing polyethylene glycol (PEG). After optimization, diffracting crystals of tPBP2 (diluted in either TNG or PNG buffers) were obtained after 3-4 weeks at 18 o C in 35-40% PEG 600 and 0.1 M CHES buffered at pH range 9.0-9.7 in both hanging and sitting drop configuration.
Apo-and phosphate-bound structures: Crystals of tPBP2 were flash-frozen in liquid nitrogen and data were collected at a wavelength of 1.0 Å using the SER-CAT 22-ID beamline at the Advanced Photon Source (APS), Argonne National Laboratory, IL. 360 o of data were collected on a Rayonix MX300 HS detector in 0.5 o oscillations with 0.3 s exposures with a crystal-to-plate distance of 160 mm. Data were processed and scaled with HKL2000 (50). tPBP2 APO was solved by molecular replacement using PHASER (51) in which the search model was the crystal structure of the TPase domain of PBP2 derived from the penicillinresistant strain FA6140 (PDB 4U3T) (18) . Data were also collected from crystals grown using protein diluted in phosphate-containing PNG buffer using the SER-CAT 22-BM beamline. 360 o of data were collected using a MAR225 imaging plate detector in 1 o oscillations with an exposure time of 3 s and a crystal-to-plate distance of 180 mm. This structure (tPBP2 PO4 ) was solved by refining the tPBP2 APO structure. Both models were refined with iterative rounds of model building and refinement using the programs COOT (52) and REFMAC (53) . The stereochemistry of the models was analyzed with PROCHECK (54) .
A non-native alanine arising from cloning was added to the N-termini of both the A and B molecules of the tPBP2 APO structure, and residues 504-512, which comprise the β3-β4 loop, could not be modelled in molecule A due to weak or absent electron density. The tPBP2 PO4 model begins with Leu237 in both molecules A and B, and similarly, residues 503-513 (molecule A) and 501-511 (molecule B) of the β3-β4 loop could not be modelled. Leu447 occupies a disallowed region of Ramachandran plot in both structures. The electron density for this residue is unambiguous and therefore is a biological outlier.
Acylated structures: Crystals of tPBP2 prepared from protein diluted in TNG buffer were soaked for 5-7 mins in 50 mM cefixime or ceftriaxone (Sigma-Aldrich, St. Louis, USA), followed by cryo-freezing as above. For the ceftriaxone complex, data were collected on an EIGER 16M detector at the SER CAT 22-ID beamline. 180° data were collected in 0.25° increments with an exposure time of 0.25 s per frame and a crystal-to-plate distance of 240 mm. For the cefixime complex, data were collected on a Rayonix MX300 HS detector at SER CAT 22-BM beamline. 180° data were collected in 1° increments with an exposure time of 6 s per frame and the crystal-to-plate distance was 260 mm. In both cases, the starting model for refinement was the structure of tPBP2 APO . Antibiotics were modelled based on |Fo|-|Fc| difference electron density maps, followed by iterative cycles of model building and refinement as above.
A number of non-native residues were modeled at the N termini in both the cefixime-(tPBP2 CFX ) and ceftriaxone-bound (tPBP2 CRO ) structures. Gly235 and Ala236 were modelled in both molecules of tPBP2 CFX , while molecule B also includes Gly234. Similarly, Ala236 was modelled in both molecules of tPBP2 CRO , while molecule B has an additional residue, Gly235. Except for molecule A in the structure of tPBP2 CFX , residues 505-507 exhibit comparatively weak density in the acylated structures but are included in the models. Three phosphate molecules are included in the tPBP2 CFX model. These are presumed to result from the phosphate buffer used for ion exchange chromatography. None are present in the active site. Equivalent phosphates were not observed in the tPBP2 CRO structure. Three molecules of PEG were modeled in the tPBP2 CFX structure and one in the tPBP2 CRO structure. A molecule of unreacted ceftriaxone was observed the tPBP2 CRO structure between molecule B and its symmetry-related counterpart (Fig. S11) . The |Fo|-|Fc| electron density map reveals most of the molecule, although density for R2 group is less clear. This binding at a symmetry contact is considered an artifact. As in the tPBP2 APO 
